指南与共识结核与非结核分枝杆菌病毒性肝炎医院感染防控

ESCMID 免疫功能受损宿主感染研究组(ESGICH)关于靶向与生物治疗安全性的共识文件:感染病学视角(可溶性免疫效应分子[I]:抗肿瘤坏死因子-α药物)

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).
指南 / 共识 · Clin Microbiol Infect · 2018-02-06

该共识文件由 ESCMID 免疫功能受损宿主感染研究组制定,基于 MEDLINE 检索综述抗 TNF-α 药物(英夫利西单抗、阿达木单抗、戈利木单抗、赛妥珠单抗聚乙二醇化、依那西普)的感染安全性。抗 TNF-α 治疗与活动性结核及其他肉芽肿性疾病风险增加两至四倍相关,依那西普风险似乎较低。建议治疗前筛查潜伏性结核和慢性乙肝,必要时给予抗结核治疗或抗病毒预防,并接种肺炎球菌和适龄疫苗。

要点

  • 抗 TNF-α 治疗与活动性结核风险增加两至四倍相关,依那西普风险似乎较低。
  • 治疗前应筛查潜伏性结核和慢性乙肝,阳性者给予相应治疗或预防。
  • 不建议常规使用抗菌、抗肺孢子菌或抗真菌预防,可接种肺炎球菌和流感疫苗。

核心结论

  • 抗 TNF-α 治疗增加活动性结核及其他肉芽肿性疾病风险两至四倍,主要源于潜伏感染再激活。

研究设计与样本

  • ESCMID 免疫功能受损宿主感染研究组(ESGICH)制定的共识文件,基于计算机 MEDLINE 检索,以各药物或治疗家族的 MeSH 词为检索词。

主要发现

  • 抗 TNF-α 治疗(英夫利西单抗、阿达木单抗、戈利木单抗、赛妥珠单抗聚乙二醇化及依那西普)与活动性结核及其他肉芽肿性疾病风险增加两至四倍相关。
  • 抗 TNF-α 治疗可能导致其他严重感染(细菌、真菌、机会性及某些病毒感染)。
  • 依那西普相关的上述风险似乎低于其他抗 TNF-α 药物。

关键数值与推荐

  • 开始抗 TNF-α 治疗前应筛查潜伏性结核感染,若合适则后续给予抗结核治疗。
  • 建议筛查慢性乙型肝炎病毒感染,乙肝表面抗原阳性个体可能需要抗病毒预防。
  • 预期抗菌、抗肺孢子菌或抗真菌预防无获益。
  • 应接种肺炎球菌疫苗和适龄抗病毒疫苗(如流感疫苗)。
  • 减毒活疫苗(如水痘-带状疱疹病毒或麻疹-腮腺炎-风疹疫苗)在接受抗 TNF-α 治疗者中可能禁忌,但需更多数据才能做出明确推荐。

临床怎么用

  • 在接受抗 TNF-α 治疗的个体中应实施预防措施,以降低潜伏性结核或乙肝再激活风险。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The present review is part of the ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies. AIMS: To review, from an Infectious Diseases perspective, the safety profile of agents targeting tumour necrosis factor-α (TNF-α) and to suggest preventive recommendations. SOURCES: Computer-based MEDLINE searches with MeSH terms pertaining to each agent or therapeutic family. CONTENT: Preclinical and clinical evidence indicate that anti-TNF-α therapy (infliximab, adalimumab, golimumab, certolizumab pegol and etanercept) is associated with a two-to four-fold increase in the risk of active tuberculosis and other granulomatous conditions (mostly resulting from the reactivation of a latent infection). In addition, it may lead to the occurrence of other serious infections (bacterial, fungal, opportunistic and certain viral infections). These associated risks seem to be lower for etanercept than other agents. Screening for latent tuberculosis infection should be performed before starting anti-TNF-α therapy, followed by anti-tuberculosis therapy if appropriate. Screening for chronic hepatitis B virus (HBV) infection is also recommended, and antiviral prophylaxis may be warranted for hepatitis B surface antigen-positive individuals. No benefit is expected from the use of antibacterial, anti-Pneumocystis or antifungal prophylaxis. Pneumococcal and age-appropriate antiviral vaccinations (i.e. influenza) should be administered. Live-virus vaccines (i.e. varicella-zoster virus or measles-mumps-rubella) may be contraindicated in people receiving anti-TNF-α therapy, although additional data are needed before definitive recommendations can be made. IMPLICATIONS: Prevention measures should be implemented to reduce the risk of latent tuberculosis or HBV reactivation among individuals receiving anti-TNF-α therapy.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Baddley JW, Cantini F, Goletti D, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents). Clin Microbiol Infect. 2018. PMID: 29459143. doi:10.1016/j.cmi.2017.12.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。